Compare BioNTech SE - ADR (BNTX) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs ProShares Ultra QQQ ETF — how do they compare? BioNTech SE - ADR trades at $92 (market cap $23.31B), while ProShares Ultra QQQ ETF trades at $92.55. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | QLD | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $119.34 | $100.53 |
52-Week Low | $83.89 | $57.16 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
